1. Brosteanu, O., Houben, P., Ihrig, K., Ohmann, C., Paulus, U., Pfistner, B., Schwarz, G., Strenge-Hesse, A., & Zettelmeyer, U. (2009). Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials. Clinical Trials, 6, 585–596.
2. Connell, C. M., Shaw, B., Holmes, S. B., & Forster, N. L. (2001). Caregivers’ attitudes toward their family members’ participation in Alzheimer disease research: Implications for recruitment and retention. Alzheimer Disease and Associated Disorders, 15, 137–145.
3. Curtin, F., & Schulz, P. (2011). Assessing the benefit: Risk ratio of a drug–randomized and naturalistic evidence. Dialogues in Clinical Neuroscience, 13, 183–190.
4. Deutscher Bundestag. (2004). Arzneimittelgesetz (AMG-04) (1976/2004) incl. 12. Novelle.
5. Deutscher Bundestag. (2010). Sozialgesetzbuch (SGB), Fünftes Buch (V), Gesetzliche Krankenversicherung. Zuletzt geändert durch Art. 2 G v. 22.12.2010 I 2309. http://wwwzahnaerzte-wlde/webtest/Internet_ZAEKnsf/66a4836bca0a3292c125741f00363d72/2ea079ee49c03956c12578a800451723/$FILE/SGB%20V%20Stand%2003-2011pdf